This section is for screenreader users or other non-CSS users for enhanced accessibility

Extra Help

For your patients with type 2 diabetes

Onglyza® (saxagliptin) is a treatment for your patients with type 2 diabetes on monotherapy who need extra help when their HbA1c levels begin to rise above 7%.

Quick reference for prescribing Onglyza

  • +Indications & Use Onglyza® (saxagliptin) is indicated for the treatment of type 2 diabetes as an add-on combination therapy - MORE
  • +Dosing & Administration One 5 mg tablet as a once-daily dose at any time of the day - MORE
  • +Contraindications Avoid if hypersensitivity to Onglyza or its excipients and take precautions in certain patient groups - MORE
  • +Known Drug Interactions The risk is low for clinically meaningful interactions - MORE
  • +Side Effects Data from 6 clinical trials documented the frequency of possible adverse events - MORE

Refer to full prescribing info

 

Thank you for visiting www.onglyza.eu.

You are now leaving this AstraZeneca site to go to another website.

Bristol-Myers SquibbWorking Together In DiabetesAstraZeneca

Thank you for visiting www.onglyza.eu.

You are now leaving this site to go to another AstraZeneca website.

Bristol-Myers SquibbWorking Together In DiabetesAstraZeneca

Welcome to the international Onglyza® (saxagliptin) website for healthcare professionals

This website is an international information resource intended for international healthcare professionals with an interest in Onglyza® (saxagliptin) and the treatment of type 2 diabetes. Please choose which site you require.

While the internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of Onglyza® (saxagliptin) may not be the same in different countries. Information on this site is based on the Summary of Product Characteristics (SPC) for Onglyza® (saxagliptin) in the EU. Please refer to your local Prescribing Information for full details.

By clicking on the link below you are declaring and confirming that you are a healthcare professional.



This website as with other AstraZeneca websites uses cookies to function and collect information on visitor activity. By continuing to use this website you acknowledge your consent to the placement and use of cookies. Further information on our cookie policy and how to delete them can be read within our Privacy Policy.

Other Onglyza® (saxagliptin) websites for
healthcare professionals only:

Confirm

Information for patients and members of the press:

PATIENTS: This website is intended for healthcare professionals only. If you are a patient, you can download Onglyza patient information here

If you are a patient, you should contact your physician if you have any questions related to type 2 diabetes, or any drug used to treat this condition.

PRESS: If you are a member of the press, you should visit the AstraZeneca Press Office.